186 related articles for article (PubMed ID: 10992004)
41. Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958.
Hawkinson JE; Szoke BG; Garofalo AW; Hom DS; Zhang H; Dreyer M; Fukuda JY; Chen L; Samant B; Simmonds S; Zeitz KP; Wadsworth A; Liao A; Chavez RA; Zmolek W; Ruslim L; Bova MP; Holcomb R; Butelman ER; Ko MC; Malmberg AB
J Pharmacol Exp Ther; 2007 Aug; 322(2):619-30. PubMed ID: 17470643
[TBL] [Abstract][Full Text] [Related]
42. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
Cirillo R; Gillio Tos E; Schwarz MK; Quattropani A; Scheer A; Missotten M; Dorbais J; Nichols A; Borrelli F; Giachetti C; Golzio L; Marinelli P; Thomas RJ; Chevillard C; Laurent F; Portet K; Barberis C; Chollet A
J Pharmacol Exp Ther; 2003 Jul; 306(1):253-61. PubMed ID: 12660315
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist.
Ransom RW; Harrell CM; Reiss DR; Murphy KL; Chang RS; Hess JF; Miller PJ; O'Malley SS; Hey PJ; Kunapuli P; Su DS; Markowitz MK; Wallace MA; Raab CE; Jones AN; Dean DC; Pettibone DJ; Freidinger RM; Bock MG
Eur J Pharmacol; 2004 Sep; 499(1-2):77-84. PubMed ID: 15363953
[TBL] [Abstract][Full Text] [Related]
44. SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'methyl-4'-(5-methyl-1,2,3-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): a novel, potent and selective 5-HT1B receptor antagonist.
Scott C; Langmead CJ; Clarke KL; Wyman P; Smith PW; Starr KR; Dawson LA; Price GW; Hagan JJ; Watson J
Neuropharmacology; 2006 Jun; 50(8):984-90. PubMed ID: 16546225
[TBL] [Abstract][Full Text] [Related]
45. Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.
Geldenhuys WJ; Kuzenko SR; Simmons MA
J Med Chem; 2010 Nov; 53(22):8080-8. PubMed ID: 21047106
[TBL] [Abstract][Full Text] [Related]
46. [3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
Moreland RB; Terranova MA; Chang R; Uchic ME; Matulenko MA; Surber BW; Stewart AO; Brioni JD
Eur J Pharmacol; 2004 Aug; 497(2):147-54. PubMed ID: 15306199
[TBL] [Abstract][Full Text] [Related]
47. GR196429: a nonindolic agonist at high-affinity melatonin receptors.
Beresford IJ; Browning C; Starkey SJ; Brown J; Foord SM; Coughlan J; North PC; Dubocovich ML; Hagan RM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1239-45. PubMed ID: 9618428
[TBL] [Abstract][Full Text] [Related]
48. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.
Dawson LA; Cato KJ; Scott C; Watson JM; Wood MD; Foxton R; de la Flor R; Jones GA; Kew JN; Cluderay JE; Southam E; Murkitt GS; Gartlon J; Pemberton DJ; Jones DN; Davies CH; Hagan J
Neuropsychopharmacology; 2008 Jun; 33(7):1642-52. PubMed ID: 17728699
[TBL] [Abstract][Full Text] [Related]
49. Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist.
Emonds-Alt X; Proietto V; Steinberg R; Advenier C; Daoui S; Naline E; Gueudet C; Michaud JC; Oury-Donat F; Poncelet M; Vilain P; Le Fur G; Maffrand JP; Soubrié P; Pascal M
Can J Physiol Pharmacol; 2002 May; 80(5):482-8. PubMed ID: 12056557
[TBL] [Abstract][Full Text] [Related]
50. Tachykinin peptides affect differently the second messenger pathways after binding to CHO-expressed human NK-1 receptors.
Sagan S; Chassaing G; Pradier L; Lavielle S
J Pharmacol Exp Ther; 1996 Mar; 276(3):1039-48. PubMed ID: 8786533
[TBL] [Abstract][Full Text] [Related]
51. Synthesis of 2-(4-biphenylyl)quinoline-4-carboxylate and carboxamide analogs. New human neurokinin-3 (hNK-3) receptor antagonists.
Saudi MN; Rostom SA; Fahmy HT; El Ashmawy IM
Arch Pharm (Weinheim); 2003 Jun; 336(3):165-74. PubMed ID: 12822182
[TBL] [Abstract][Full Text] [Related]
52. Effects of the peripherally acting NK receptor antagonist, SB-235375, on intestinal and somatic nociceptive responses and on intestinal motility in anaesthetized rats.
Shafton AD; Bogeski G; Kitchener PD; Lewis VA; Sanger GJ; Furness JB
Neurogastroenterol Motil; 2004 Apr; 16(2):223-31. PubMed ID: 15086876
[TBL] [Abstract][Full Text] [Related]
53. In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists.
Suzuki G; Tsukamoto N; Fushiki H; Kawagishi A; Nakamura M; Kurihara H; Mitsuya M; Ohkubo M; Ohta H
J Pharmacol Exp Ther; 2007 Oct; 323(1):147-56. PubMed ID: 17609420
[TBL] [Abstract][Full Text] [Related]
54. SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor.
Serradeil-Le Gal C; Valette G; Foulon L; Germain G; Advenier C; Naline E; Bardou M; Martinolle JP; Pouzet B; Raufaste D; Garcia C; Double-Cazanave E; Pauly M; Pascal M; Barbier A; Scatton B; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 2004 Apr; 309(1):414-24. PubMed ID: 14722330
[TBL] [Abstract][Full Text] [Related]
55. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
Juszczak M; Boczek-Leszczyk E; Stempniak B
J Physiol Pharmacol; 2007 Dec; 58(4):829-43. PubMed ID: 18195491
[TBL] [Abstract][Full Text] [Related]
56. Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
Nakazato A; Sakagami K; Yasuhara A; Ohta H; Yoshikawa R; Itoh M; Nakamura M; Chaki S
J Med Chem; 2004 Aug; 47(18):4570-87. PubMed ID: 15317467
[TBL] [Abstract][Full Text] [Related]
57. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.
Gully D; Labeeuw B; Boigegrain R; Oury-Donat F; Bachy A; Poncelet M; Steinberg R; Suaud-Chagny MF; Santucci V; Vita N; Pecceu F; Labbé-Jullié C; Kitabgi P; Soubrié P; Le Fur G; Maffrand JP
J Pharmacol Exp Ther; 1997 Feb; 280(2):802-12. PubMed ID: 9023294
[TBL] [Abstract][Full Text] [Related]
58. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist.
Lavreysen H; Wouters R; Bischoff F; Nóbrega Pereira S; Langlois X; Blokland S; Somers M; Dillen L; Lesage AS
Neuropharmacology; 2004 Dec; 47(7):961-72. PubMed ID: 15555631
[TBL] [Abstract][Full Text] [Related]
59. Neurokinin A and senktide attenuate scopolamine-induced impairment of spontaneous alternation performance in mice.
Ukai M; Shinkai N; Kameyama T
Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Jun; 16(3):97-101. PubMed ID: 8905797
[TBL] [Abstract][Full Text] [Related]
60. Pharmacological properties of FK886, a new, centrally active neurokinin-1 receptor antagonist.
Yoshino-Furukawa T; Maeda Y; Kikuchi A; Sakuma H; Imazumi K; Yamakuni H; Sogabe H; Matsuo M; Manda T; Uchida W
Biol Pharm Bull; 2013; 36(1):76-81. PubMed ID: 23302639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
